4.7 Review

Delivery of therapeutic oligonucleotides with cell penetrating peptides

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 87, Issue -, Pages 52-67

Publisher

ELSEVIER
DOI: 10.1016/j.addr.2015.02.008

Keywords

Cell penetrating peptides; Delivery; Antisense oligonucleotides; Splice switching oligonucleotides; siRNAs

Funding

  1. French muscular dystrophy association AFM [14784]
  2. Medical Research Council [U105178803]
  3. AFM
  4. FEDER (Fonds Europeen de Developpement Regional)/La Region Languedoc-Roussillon
  5. Agence Nationale de la Recherche (ANR)
  6. Centre National de la Recherche Scientifique (CNRS)
  7. MRC [MC_U105178803, G0900887] Funding Source: UKRI
  8. Medical Research Council [G0900887, MC_U105178803] Funding Source: researchfish

Ask authors/readers for more resources

Oligonucleotide-based drugs have received considerable attention for their capacity to modulate gene expression very specifically and as a consequence they have found applications in the treatment of many human acquired or genetic diseases. Clinical translation has been often hampered by poor biodistribution, however. Cell-penetrating peptides (CPPs) appear as a possibility to increase the cellular delivery of non-permeant biomolecules such as nucleic acids. This review focuses on CPP-delivery of several classes of oligonudeotides (ONs), namely antisense oligonucleotides, splice switching oligonucleotides (SSOs) and siRNAs. Two main strategies have been used to transport ONs with CPPs: covalent conjugation (which is more appropriate for charge-neutral ON analogues) and non-covalent complexation (which has been used for siRNA delivery essentially). Chemical synthesis, mechanisms of cellular internalization and various applications will be reviewed. A comprehensive coverage of the enormous amount of published data was not possible. Instead, emphasis has been put on strategies that have proven to be effective in animal models of important human diseases and on examples taken from the authors' own expertise. (C) 2015 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available